Table 1 Baseline Characteristics of Patients
Baseline characteristics of patients | |||
|---|---|---|---|
Characteristic | DAC group (14) | Control group (12) | P value |
Gender | |||
Male | 10 (71.4%) | 5 (41.7%) | 0.233 |
Female | 4 (28.6%) | 7 (58.3%) | |
Age, median | 26.5 (8–52) | 31 (16–74) | 0.226 |
Ph + ALL, n (%) | 2 (14.3%) | 5 (41.7%) | 0.190 |
Ph-like ALL, n (%) | 3 (21.4%) | 2 (16.7%) | 1.000 |
White blood cell ≥ 50 × 10^9/L, n (%) | 6 (42.9%) | 2 (16.7%) | 0.216 |
Extramedullary leukemia, n (%) | 2 (14.3%) | 0 (0%) | 0.483 |
Monosomal karyotype, n (%) | 0 (0%) | 1 (8.3%) | 0.462 |
Complex karyotype, n (%) | 2 (14.3%) | 2 (16.7%) | 1.000 |
KMT2A rearranged, n (%) | 1 (7.1%) | 0 (0%) | 1.000 |
TP53 mutation or deletion, n (%) | 2 (14.3%) | 0 (0%) | 0.483 |
T315I mutation, n (%) | 1 (7.1%) | 2 (16.7%) | 0.580 |
Poor-risk cytogenetics, n (%) | 8 (57.1%) | 8 (66.7%) | 0.701 |
Prior cycles of therapy, median (range) | 4 (2–16) | 6.5 (1–20) | 0.251 |
< 5 cycles of therapy, n (%) | 9 (64.3%) | 4 (33.3%) | 0.235 |
≥ 5 and < 10 lines of therapy, n (%) | 2 (14.3%) | 5 (41.7%) | |
≥ 10 cycles of therapy, n (%) | 3 (21.4%) | 3 (25%) | |
Primary refractory to chemotherapy, n (%) | 2 (14.3%) | 3 (25%) | 0.635 |
Numbers of relapses, median (range) | 1 (0–2) | 1 (0–2) | 0.685 |
Relapse after previous HSCT, n (%) | |||
Yes | 6 (42.9%) | 0 (0%) | 0.017 |
No | 8 (57.1%) | 12 (100%) | |
Blasts in BM before lymphodepletion treatment, median (range) | 35.75 (5–82) | 43.75 (6–85.5) | 0.487 |
LDH, pre-lymphodepletion, median (range) | 173.8 (106.5–644) | 168.7 (83.6–722.2) | 0.956 |
Ferritin, pre-lymphodepletion, median (range) | 774.945 (234.06–2718.84) | 1614.66 (411.63–2663.69) | 0.140 |
CRP, pre-lymphodepletion, median (range) | 5.115 (0.28–15.36) | 1.195 (0.12–15.36) | 0.170 |
ECOG, pre-lymphodepletion, median (range) | 2 (1–3) | 2 (1–3) | 0.609 |
CAR T-cell dose, 10^7/kg, median (range) | 1 (0.5–2) | 1 (0.5–2.5) | 0.950 |
Source of CAR T-cells, n (%) | |||
Autologous | 10 (71.4%) | 12 (100%) | 0.100 |
Donor-derived allogenic | 4 (28.6%) | 0 (0%) | |
Transduction rate (%), median | 31.435 (13.02–64.35) | 44.685 (6.07–63.92) | 0.643 |